Gilead scores US approval for breast cancer drug that wowed ESMOGilead’s $21 billion purchase of Immunomedics and its potential blockbuster Trodelvy continues to pay off, as the drug Share XGilead scores US approval for breast cancer drug that wowed ESMOhttps://pharmaphorum.com/news/gilead-scores-us-approval-for-breast-cancer-drug-that-wowed-esmo/
Novartis expands in radio-oncology again with $1.3bn Artios allianceIn its second licensing deal in the radio-oncology area in consecutive weeks, Novartis has agreed a $1.3 billion-plus Share XNovartis expands in radio-oncology again with $1.3bn Artios alliancehttps://pharmaphorum.com/news/novartis-expands-in-radio-oncology-again-with-1-3bn-artios-alliance/
Sanofi’s Sarclisa gains new US multiple myeloma indicationThe FDA has approved Sanofi’s Sarclisa (isatuximab) in combination with a new chemotherapy regimen for advanced multiple myeloma, Share XSanofi’s Sarclisa gains new US multiple myeloma indicationhttps://pharmaphorum.com/news/sanofis-sarclisa-gains-new-us-multiple-myeloma-indication/
Pyxis follows Pfizer alliance with $152m fundraising for cancer pipelineFresh from a licensing agreement with Pfizer, US startup Pyxis Oncology has raised a sizeable $152 million in Share XPyxis follows Pfizer alliance with $152m fundraising for cancer pipelinehttps://pharmaphorum.com/news/pyxis-follows-pfizer-alliance-with-152m-fundraising-for-cancer-pipeline/
TG Therapeutics completes FDA filing for Roche challenger in CLLTG Therapeutics has completed its rolling FDA filing for its U2 combination therapy consisting of the antibody ublituximab Share XTG Therapeutics completes FDA filing for Roche challenger in CLLhttps://pharmaphorum.com/news/tg-therapeutics-completes-fda-filing-for-roche-challenger-in-cll/
FDA approves BMS’ multiple myeloma CAR-T AbecmaThe FDA has approved Bristol-Myers Squibb’s Abecma (idecabtagene vicleucel) for multiple myeloma, the first cell therapy to treat Share XFDA approves BMS’ multiple myeloma CAR-T Abecmahttps://pharmaphorum.com/news/fda-approves-bms-multiple-myeloma-car-t-abecma/
Cancer services should be rebuilt after COVID disruption, experts sayThere is a pressing need for a joined-up cancer strategy to reverse the impact of the COVID-19 pandemic, Share XCancer services should be rebuilt after COVID disruption, experts sayhttps://pharmaphorum.com/news/cancer-services-should-be-rebuilt-after-covid-19-disruption-report/
Novartis’ radioligand therapy meets phase 3 prostate cancer trial targetNovartis’ radioligand therapy Lu-PSMA-617 has met its target in prostate cancer, as its $2.1 billion acquisition of specialist Share XNovartis’ radioligand therapy meets phase 3 prostate cancer trial targethttps://pharmaphorum.com/news/novartis-radioligand-therapy-meets-target-in-prostate-cacner/
Aura raises $80m to develop its virus-like cancer drugsUS biotech Aura Biosciences has closed an oversubscribed financing, raising $80 million to help take its lead virus-like Share XAura raises $80m to develop its virus-like cancer drugshttps://pharmaphorum.com/news/aura-raises-80m-to-develop-its-virus-like-cancer-drugs/
Belgium’s eTheRNA gets EU grant to develop mRNA cancer vaccinesBelgian immunotherapy firm eTheRNA has received a €6.9 million grant from the European Commission to accelerate clinical development Share XBelgium’s eTheRNA gets EU grant to develop mRNA cancer vaccineshttps://pharmaphorum.com/news/belgiums-etherna-gets-eu-grant-to-develop-mrna-cancer-vaccines/
Merck gets confirmatory trial win for Keytruda in endometrial cancerMerck & Co’s conditional FDA approval for checkpoint inhibitor Keytruda in endometrial cancer looks secure, thanks to a Share XMerck gets confirmatory trial win for Keytruda in endometrial cancerhttps://pharmaphorum.com/news/merck-gets-confirmatory-trial-win-for-keytruda-in-endometrial-cancer/
Rubius launches $200m IPO to fund red blood cell therapiesRubius Therapeutics has announced the pricing of its Nasdaq IPO, aiming to raise $200 million towards its novel Share XRubius launches $200m IPO to fund red blood cell therapieshttps://pharmaphorum.com/news/rubius-launches-200m-ipo-for-red-blood-cell-therapies/
GSK’s big-ticket cancer alliance with Merck KGaA stumbles againMerck KGaA’s bispecific cancer candidate bintrafusp alfa has failed a second clinical trial in the space of a Share XGSK’s big-ticket cancer alliance with Merck KGaA stumbles againhttps://pharmaphorum.com/news/gsks-big-ticket-cancer-alliance-with-merck-kgaa-hits-another-hurdle/
Sanofi, Regeneron prep filings for Libtayo in cervical cancerSanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a Share XSanofi, Regeneron prep filings for Libtayo in cervical cancerhttps://pharmaphorum.com/news/sanofi-regeneron-prep-filings-for-libtayo-in-cervical-cancer/
New era of genomic medicine begins as UK approves Lilly’s RetsevmoThe UK regulator has authorised Eli Lilly’s targeted cancer drug Retsevmo for tumours with RET fusion positive lung Share XNew era of genomic medicine begins as UK approves Lilly’s Retsevmohttps://pharmaphorum.com/news/uk-authorises-lillys-ret-targeted-retsevmo/
